http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Eliza Kruger ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
PE-167: High Prevalence of Comorbidities and Contraindicated Medications in HCV Patients in Japan
( Hiroshi Yotsuyanagi ),( Eliza Kruger ),( Seng Tan ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: To determine the prevalence of comorbidities and drug-drug interactions (DDIs) in CHC patients in Japan. Methods: Patients were identified using the ICD10 code for CHC in the Japanese Medical Data Center (MDC) database (04/2008-08/2014). Prescriptions were categorized as either red (contraindicated) or amber (additional monitoring/dose reduction required) for DDI potential with at least one currently licensed direct-acting antiviral (DAA). Results: 92,294 patients were identified, average age was 68 and 52% male. 82% of patients had one or more comorbidity; the number with 6+ comorbidities increased with age from 2% of patients aged 18-34 to 17% for patients 75+. The most common were hypertension (44%), chronic gastritis (33%) and gastro-oesophageal reflux disease (32%). 74% were treated with amber DDIs and 26% were on red. Polypharmacy increased with age, from 43% for 18-34 to 82% for 75+ (amber) and from 13% to 29% for 18-34 year olds and 75+ respectively (red). Only 8.2% of patients were treated for CHC. Of these, 81% had a potential DDI, increasing from 61% for 18-34 years to 90% for 75+. Conclusions: We observed significant co-morbidity and co-prescribing with DDI potential in CHC patients in Japan. Few patients received SVR treatment, indicating a large unmet need in Japan. With the treatment shift from interferon to DAA’s, more patients may receive treatment. Hence, the high proportion of co-medications contraindicated to all DAA’s vs. only some suggests careful selection of the DAA regimen is required. Treating patients at a younger age would also reduce the risk of DDI.
-
( Young-suk Lim ),( Henry Lik Yuen Chan ),( Yock Young Dan ),( Mei Hsuan Lee ),( Eliza Kruger ),( Seng Tan5,Zobair M. Younossi ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: To estimate the work productivity gains associated with LDV/SOF treatment for CHC in Hong Kong, Singapore, South Korea and Taiwan. Methods: The model captures anticipated impact of LDV/SOF on productivity loss over a one-year time horizon from a societal perspective for each country. A literature review was performed to identify country- specific inputs and expert advice was solicited to verify key variables. Patients enter the model post-treatment, having achieved SVR12, or not. Absenteeism and presenteeism rates were estimated based on the Work Productivity and Activity Index-Specific Health Problem (WPAI-SHP) data collected from the Phase III ION trials (US participants only) at baseline and at 12 weeks with rates assumed to remain unchanged from baseline for patients not achieving SVR. Sensitivity analyses were performed on key variables. Results: Total Work productivity loss due to not treating CHC was highest in Taiwan at US$349M ($355 per capita) given high prevalence of HCV, followed by US$146M ($358) in Korea, US$17M ($914) in Singapore and US$11M ($351) in Hong Kong. Treatment with LDV/SOF resulted in estimated productivity gains of $138 million, $58.7 million, $6.8 million and $4.5 million in Taiwan, Korea, Singapore and Hong Kong respectively. Conclusions: CHC imposes a significant indirect economic burden. Our model demonstrates that treatment of HCV GT1 patients with LDV/SOF is likely to result in significant cost savings due to an improvement in presenteeism versus no treatment across 4 Asian countries. This indirect economic gain should be considered when assessing the benefits of treating CHC.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
